m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03176
 [1]
Histone modification H3K9Ac CBP RBM15 Direct Enhancement m6A modification CXCL11 CXCL11 RBM15 Methylation : m6A sites
m6A Modification:
m6A Regulator RNA-binding motif protein 15 (RBM15) WRITER
 Regulator Info 
m6A Target C-X-C motif chemokine 11 (CXCL11)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator CREB-binding protein (CREBBP) WRITER View Details
Regulated Target Histone H3 lysine 9 acetylation (H3K9Ac) View Details
Downstream Gene RBM15 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of C-X-C motif chemokine 11 (CXCL11). Enhanced RBM15 was caused by the abundant H3K27ac/Histone H3 lysine 9 acetylation (H3K9ac) of the RBM15 promoter induced by EP300/CREBBP.
Responsed Disease Renal cell carcinoma of kidney ICD-11: 2C90.0
 Disease Info 
Responsed Drug SETDB1-TTD-IN-1
 Drug Info 
Pathway Response mRNA surveillance pathway hsa03015
RNA degradation hsa03018
Cell Process RNA stability
In-vitro Model
 THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
HK-2 [Human kidney] Normal Homo sapiens CVCL_0302
786-O Renal cell carcinoma Homo sapiens CVCL_1051
Caki-1 Clear cell renal cell carcinoma Homo sapiens CVCL_0234
Caki-2 Papillary renal cell carcinoma Homo sapiens CVCL_0235
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CREB-binding protein (CREBBP) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PRI-724 Phase 1/2 [2]
MOA Modulator
External Link
CID: 71509318
TTD: D0Q0ZY
DrugBank: DB15034
 Compound Name C 82 Phase 1/2 [3]
Synonyms
N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75202656
TTD: D0DA5M
 Compound Name CCS1477 Phase 1/2 [4]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [5]
MOA Inhibitor
External Link
TTD: DT8IL6
 Compound Name Pyrrolo-pyrrolone derivative 6 Patented [6]
Synonyms
PMID26924192-Compound-39
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 91 nM
External Link
CID: 122553484
TTD: D0O9WQ
 Compound Name ischemin Investigative [7]
Synonyms
MS120
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
CID: 135566302
TTD: D00DXI
 Compound Name SGC-CBP30 Investigative [8]
Synonyms
1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30 nM
External Link
CID: 72201027
TTD: D03XXT
 Compound Name I-CBP112 Investigative [9]
Synonyms
1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 440 nM
External Link
CID: 90488984
TTD: D0J3JI
2C90: Renal cell carcinoma 76 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [10]
External Link
TTD: D0YM2K
 Compound Name Tivozanib Approved [11]
Synonyms
ASP4130/AV-951
    Click to Show/Hide
External Link
CID: 9911830
TTD: D0W7JZ
DrugBank: DB11800
 Compound Name Sorafenib Approved [12]
Synonyms
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
    Click to Show/Hide
External Link
CID: 216239
TTD: D0W5HK
DrugBank: DB00398
 Compound Name Lenvatinib Approved [10]
Synonyms
E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 9823820
TTD: D0R0FO
DrugBank: DB09078
 Compound Name Belzutifan Approved [13]
Synonyms
MK-6482
    Click to Show/Hide
External Link
CID: 117947097
TTD: D0NU8J
 Compound Name Reniale Approved [14]
Synonyms
Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova
    Click to Show/Hide
External Link
TTD: D0N7KV
 Compound Name Romidepsin Approved [15]
Synonyms
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
    Click to Show/Hide
External Link
CID: 5352062
TTD: D0L7LC
DrugBank: DB06176
 Compound Name Avelumab Approved [10]
External Link
TTD: D0K7SX
 Compound Name Everolimus Approved [16]
Synonyms
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
    Click to Show/Hide
External Link
CID: 6442177
TTD: D0K3QS
DrugBank: DB01590
 Compound Name Pazopanib HCl Approved [17]
Synonyms
Votrient (TN)
    Click to Show/Hide
External Link
CID: 11525740
TTD: D0F0ZY
 Compound Name Temsirolimus Approved [18]
Synonyms
Torisel
    Click to Show/Hide
External Link
CID: 6918289
TTD: D0ES1Q
 Compound Name Pembrolizumab Approved [10]
External Link
TTD: D08ANZ
 Compound Name CreaVax-RCC Approved [19]
Synonyms
Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene
    Click to Show/Hide
External Link
TTD: D06KPV
 Compound Name Aldesleukin Approved [20]
Synonyms
Proleukin (TN)
    Click to Show/Hide
External Link
TTD: D05PUD
 Compound Name Sifalimumab Approved [21]
Synonyms
Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
    Click to Show/Hide
External Link
TTD: D05NDR
 Compound Name BOL-303259-X Phase 3 [22]
Synonyms
Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
    Click to Show/Hide
External Link
CID: 11156438
TTD: D05LQX
DrugBank: DB11660
 Compound Name Axitinib Approved [23]
Synonyms
AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
    Click to Show/Hide
External Link
CID: 6450551
TTD: D01ZRI
DrugBank: DB06626
 Compound Name Nivolumab Approved [10]
External Link
TTD: D00GOV
 Compound Name HBI-8000 Phase 1/2 [10]
Synonyms
CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
    Click to Show/Hide
External Link
CID: 12136798
TTD: D00SQN
DrugBank: DB06334
 Compound Name Human coagulation factor X BLA submitted [24]
External Link
TTD: D07JEW
 Compound Name Trebananib Phase 3 [25]
External Link
TTD: D9NL3R
 Compound Name Abexinostat Phase 3 [26]
Synonyms
PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
    Click to Show/Hide
External Link
CID: 11749858
TTD: D0V0SL
DrugBank: DB12565
 Compound Name Vitespen Phase 3 [27]
Synonyms
Oncophage (TN)
    Click to Show/Hide
External Link
TTD: D0UK2Z
 Compound Name AMD-070 Phase 3 [10]
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
    Click to Show/Hide
External Link
CID: 11256587
TTD: D0O2XQ
DrugBank: DB05501
 Compound Name Nivolumab + ipilimumab Phase 3 [28]
External Link
TTD: D0N5GV
 Compound Name Savolitinib Phase 3 [10]
Synonyms
1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
    Click to Show/Hide
External Link
CID: 68289010
TTD: D0LW0T
DrugBank: DB12048
 Compound Name Rocapuldencel-T Phase 3 [29]
External Link
TTD: D0J0GR
 Compound Name Cotellic Phase 3 [10]
Synonyms
Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate
    Click to Show/Hide
External Link
CID: 16222096
TTD: D0FJ9I
DrugBank: DB05239
 Compound Name BMS-986205 Phase 3 [10]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name TKI258 Phase 3 [30]
Synonyms
Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
    Click to Show/Hide
External Link
CID: 135611162
TTD: D07OZR
 Compound Name AM0010 Phase 3 [28]
External Link
TTD: D03MYX
 Compound Name IMA-901 Phase 3 [31]
Synonyms
TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics
    Click to Show/Hide
External Link
TTD: D02UNP
 Compound Name NKTR 214 Phase 3 [28]
External Link
TTD: D02QQE
 Compound Name TRC105 Phase 2 [28]
External Link
TTD: D00YQI
 Compound Name CAP-232 Phase 2a [32]
Synonyms
TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01
    Click to Show/Hide
External Link
CID: 6918265
TTD: D09EFC
DrugBank: DB12088
 Compound Name CMN-001 Phase 2 [33]
External Link
TTD: DVQ1F5
 Compound Name DS-3201b Phase 2 [34]
Synonyms
Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
    Click to Show/Hide
External Link
CID: 126481870
TTD: DNM79H
 Compound Name AGS-16C3F Phase 2 [10]
External Link
TTD: D0XT5Q
 Compound Name TV-Kidney-1 Phase 2 [29]
External Link
TTD: D0WZ0E
 Compound Name IMO-2055 Phase 2 [35]
External Link
TTD: D0W6HO
 Compound Name Anti-LAG3 Phase 2 [28]
External Link
TTD: D0T7OI
 Compound Name AGS-003 Phase 2 [36]
External Link
TTD: D0Q5OC
 Compound Name Ispinesib Phase 2 [37]
Synonyms
SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
    Click to Show/Hide
External Link
CID: 6851740
TTD: D0PW4N
DrugBank: DB06188
 Compound Name Ilixadencel Phase 2 [10]
External Link
TTD: D0PR4O
 Compound Name CRLX101 Phase 2 [10]
External Link
CID: 184196
TTD: D0ND9T
 Compound Name FolateImmune Phase 2 [38]
Synonyms
Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5
    Click to Show/Hide
External Link
CID: 135564966
TTD: D0N8JG
DrugBank: DB12559
 Compound Name Varlilumab Phase 2 [10]
External Link
TTD: D0KV3M
 Compound Name TVI-Kidney-1 Phase 2 [39]
External Link
TTD: D0JH5K
 Compound Name OSI-027 Phase 2 [40]
External Link
CID: 135398516
TTD: D0H7XL
DrugBank: DB12387
 Compound Name XL880 Phase 2 [41]
Synonyms
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
    Click to Show/Hide
External Link
CID: 42642645
TTD: D0D1GF
DrugBank: DB12307
 Compound Name Girentuximab I-124 Phase 2 [42]
Synonyms
Redectane (TN)
    Click to Show/Hide
External Link
TTD: D0BH7Z
 Compound Name Autologous renal cell carcinoma vaccine Phase 2 [43]
External Link
TTD: D08FKD
 Compound Name RX-0201 Phase 2 [10]
External Link
TTD: D07SYZ
 Compound Name Human interleukin-2 Phase 2 [44]
Synonyms
Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice
    Click to Show/Hide
External Link
TTD: D04OJM
 Compound Name CB-839 Phase 2 [10]
External Link
CID: 71577426
TTD: D01PBW
DrugBank: DB15232
 Compound Name ATN-161 Phase 2 [45]
Synonyms
PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan
    Click to Show/Hide
External Link
CID: 9960285
TTD: D00QVT
 Compound Name TV1-Kidney-1 Phase 2 [46]
External Link
TTD: D00HMZ
 Compound Name CCT301-38 (targeting ROR2) Phase 1/2 [47]
External Link
TTD: D0RA9C
 Compound Name LAG525 Phase 1/2 [10]
External Link
TTD: D0E4LS
 Compound Name CCT301-59 (targeting ROR2) Phase 1/2 [47]
External Link
TTD: D0C2PH
 Compound Name Anti-C-met CAR-T cells Phase 1/2 [48]
External Link
TTD: D0A3OE
 Compound Name CDX-014 Phase 1/2 [10]
External Link
TTD: D09WXY
 Compound Name IL-2 XL Phase 1/2 [49]
Synonyms
IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel
    Click to Show/Hide
External Link
TTD: D08XFA
 Compound Name ARO-HIF2 Phase 1 [50]
External Link
TTD: DE8V1R
 Compound Name AGS-16 mab Phase 1 [51]
Synonyms
AGS-16M18
    Click to Show/Hide
External Link
TTD: D0X7MY
 Compound Name Neovastat Phase 1 [52]
External Link
TTD: D0T4BL
 Compound Name Biomed 101 Discontinued in Phase 1 [53]
Synonyms
SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390
    Click to Show/Hide
External Link
CID: 114999
TTD: D0S0WN
 Compound Name AMG 172 Phase 1 [54]
External Link
TTD: D0NC1Q
 Compound Name Anti-hCD70 CAR transduced PBL Phase 1 [55]
External Link
TTD: D0JO9M
 Compound Name Veglin Phase 1 [56]
External Link
TTD: D0G6GB
 Compound Name IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine Phase 1 [57]
Synonyms
RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)
    Click to Show/Hide
External Link
TTD: D04HWK
 Compound Name Vorsetuzumab mafodotin Discontinued in Phase 1 [58]
External Link
TTD: D08WTE
 Compound Name BCL-004 Investigative [59]
External Link
TTD: D09KTE
 Compound Name GM-CAIX Investigative [59]
Synonyms
GM-CSF/cancer antigen chimeric protein (renal cancer), Kite
    Click to Show/Hide
External Link
TTD: D07OQJ
 Compound Name GS-168 Investigative [59]
Synonyms
GS-168A
    Click to Show/Hide
External Link
TTD: D05YWN
 Compound Name STF-62247 Investigative [59]
Synonyms
Renal cell carcinoma therapy, Stanford University
    Click to Show/Hide
External Link
CID: 704473
TTD: D01CIN
References
Ref 1 Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radic Biol Med. 2022 May 1;184:135-147. doi: 10.1016/j.freeradbiomed.2022.03.031. Epub 2022 Apr 2.
Ref 2 Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14. doi: 10.1073/pnas.1001520107. Epub 2010 Jul 21.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 5 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 6 BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505-22. doi: 10.1517/13543776.2016.1159299. Epub 2016 Mar 15.
Ref 7 A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41. doi: 10.1016/j.chembiol.2010.12.021.
Ref 8 Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64. doi: 10.1002/cmdc.201300434. Epub 2014 Feb 4.
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
Ref 13 ClinicalTrials.gov (NCT04586231) A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011). U.S. National Institutes of Health.
Ref 14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026173)
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
Ref 17 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. doi: 10.1038/nrd3101.
Ref 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5892).
Ref 19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 20 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8257).
Ref 22 ClinicalTrials.gov (NCT01895972) A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension. U.S.National Institutes of Health.
Ref 23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5659).
Ref 24 FDA Accepts BPL's Amended BLA Submission for Coagadex (Coagulation Factor X, Human). BPL Bio Products Laboratory USA, Inc.
Ref 25 ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT03592472) A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV). U.S. National Institutes of Health.
Ref 27 ClinicalTrials.gov (NCT00033904) Survival Study Of Oncophage vs. Observation In Patients With Kidney Cancer. U.S. National Institutes of Health.
Ref 28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 29 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 30 ClinicalTrials.gov (NCT01223027) Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 31 ClinicalTrials.gov (NCT01265901) IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 32 ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT04203901) A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma. U.S.National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT04388852) DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers. U.S. National Institutes of Health.
Ref 35 Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
Ref 36 ClinicalTrials.gov (NCT01482949) A Rollover Protocol for Subjects Previously Treated With AGS-003. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT01511055) Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand. U.S. National Institutes of Health.
Ref 39 Clinical pipeline report, company report or official report of TVAX Biomedical.
Ref 40 Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406.
Ref 41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 42 ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health.
Ref 43 Clinical pipeline report, company report or official report of Dartmouth-Hitchcock Medical Center.
Ref 44 Clinical pipeline report, company report or official report of Immunservice GmbH.
Ref 45 ClinicalTrials.gov (NCT00131651) ATN-161 in Advanced Renal Cell Cancer. U.S. National Institutes of Health.
Ref 46 Rethinking Immunotherapy for Brain Tumors. Michael D. Becker, MDB Communications LLC. February 22, 2012.
Ref 47 ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Ref 48 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020218)
Ref 50 ClinicalTrials.gov (NCT04169711) Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT00816686) A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer. U.S. National Institutes of Health.
Ref 52 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 53 ClinicalTrials.gov (NCT00004890) Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT01497821) AMG 172 First in Human Study in Patients With Kidney Cancer. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ref 56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020056)
Ref 57 Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther. 2011 Apr;18(4):354-63.
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020387)
Ref 59 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.